Parenting Styles and Parental Self-Efficacy in Parents of Children with Neurological Disorders
Balneo and PRM Research Journal,
Год журнала:
2025,
Номер
16(Vol 16 No. 1), С. 778 - 778
Опубликована: Март 31, 2025
This
study
examines
the
influence
of
different
parenting
styles
on
parental
self-efficacy
in
families
with
children
diagnosed
neurologic
disorders.
Specifically,
it
explores
correlation
between
five
distinct
styles—authoritarian,
authoritative,
permissive,
perfectionist,
and
uninvolved—and
confidence
managing
challenges
associated
raising
disabilities.
The
involved
134
parents
disorders
was
conducted
a
specialized
medical
rehabilitation
center
for
Bucharest,
Romania.
Data
collected
using
Parenting
Style
Questionnaire
(PSQ)
Brief
Parental
Self-Efficacy
Scale
(BPSES).
Statistical
analyses
were
performed
Spearman's
rank-order
coefficient
(Spearman's
rho)
to
assess
monotonic
relationships,
complemented
by
nonlinear
regression
modeling
evaluate
predictive
associations.
results
showed
statistically
significant
correlations
across
genders
educational
levels.
Moderate
negative
found
authoritarian
style
both
men
(p
<
0.001,
r
=
-0.581)
women
-0.519).
A
moderate
positive
observed
authoritative
0.525).
Furthermore,
moderately
negatively
correlated
university
education
-0.601)
pre-university
-0.530).
Regression
analysis
indicated
that
predictor
diminished
self-efficacy,
explaining
32.7%
variance
outcomes.
findings
suggest
understanding
impact
is
crucial
designing
targeted
interventions
improve
confidence,
particularly
may
be
increased
intervention
programs
encourage
techniques
while
lowering
inclinations.
For
kids
neurological
diseases,
this
can
therefore
result
better
coping
strategies,
enhanced
parent-child
developmental
psychological
results.
Язык: Английский
Biomarker Evolution in Pediatric SMA: Insights from CSF pNF-H Dynamics and SMN2 Copy Number During Nusinersen Therapy
Balneo and PRM Research Journal,
Год журнала:
2025,
Номер
16(Vol 16 No. 1), С. 777 - 777
Опубликована: Март 31, 2025
Spinal
muscular
atrophy
(SMA)
is
a
severe
neurodegenerative
disorder
caused
by
insufficient
survival
motor
neuron
(SMN)
protein
synthesis,
leading
to
progressive
loss
and
debilitating
symptoms.
This
study
evaluates
cerebrospinal
fluid
(CSF)
phosphorylated
neurofilament-heavy
chain
(pNF-H)
levels
as
predictive
markers
of
function
in
73
pediatric
SMA
patients
undergoing
nusinersen
treatment.
pNF-H,
structural
component
neurons,
released
into
the
CSF
serum
during
neuronal
damage
or
degeneration.
aims
address
this
gap
assessing
pNF-H
dynamics
relation
changes
over
course
It
examines
evolution
different
time
periods
initial
clinical
biological
parameters
their
progression
at
start
treatment
response
therapy.
Patients
were
stratified
SMN2
gene
copy
number,
which
modulates
disease
severity
inversely
correlated
with
higher
indicating
more
neurodegeneration.
also
function,
baseline
linked
lower
scores.
During
treatment,
declined
alongside
improvements,
supporting
its
role
longitudinal
biomarker.
In
2
copies,
larger
early
variations
predicted
better
gains
1
years,
while
smaller
maintenance
improvement.
3
fluctuations
associated
scores,
along
creatinine
years.
Longitudinal
analyses
revealed
that
sustained
decreases
enhanced
outcomes.
The
highlights
level
robust
predictor
efficacy,
offering
insights
therapeutic
impact.
These
findings
underscore
critical
intervention
personalized
biomarker
monitoring
optimizing
quality
life
for
patients.
Язык: Английский
The Relevance of Spinal Muscular Atrophy Biomarkers in the Treatment Era
Biomedicines,
Год журнала:
2024,
Номер
12(11), С. 2486 - 2486
Опубликована: Окт. 30, 2024
Spinal
muscular
atrophy
(SMA)
is
a
severe
neuromuscular
disorder
that
currently
has
an
approved
treatment
for
all
forms
of
the
disease.
Previously,
biomarkers
were
primarily
used
diagnostic
purposes,
such
as
detecting
presence
disease
or
determining
specific
clinical
type
SMA.
Currently,
with
availability
therapy,
have
become
more
valuable
due
to
their
potential
prognostic,
predictive,
and
pharmacodynamic
applications.
This
review
describes
most
promising
physiological,
functional,
imaging
molecular
SMA,
derived
from
different
patients'
tissues.
The
summarizes
information
about
classical
are
already
in
practice
well
fresh
findings
on
been
recently
disclosed.
It
highlights
usefulness,
limitations,
strengths
each
biomarker,
indicating
purposes
which
best
suited
when
combining
them
may
be
beneficial.
Язык: Английский
Predictive Clinical-Biological Markers Over the First 3 Years of Nusinersen Treatment in SMA Type 1 Patients
Balneo and PRM Research Journal,
Год журнала:
2024,
Номер
15(Vol.15, no. 4), С. 754 - 754
Опубликована: Дек. 22, 2024
Werdnig-Hoffmann
disease,
or
type
1
Spinal
Muscular
Atrophy
(SMA),
is
caused
by
insufficient
SMN
protein
synthesis
due
to
a
genetic
defect.
Symptoms
appear
within
the
first
6
months
of
life,
and
without
ventilatory
support,
life
expectancy
averages
2
years.
This
study
aimed
monitor
pNF-H
neurofilament
levels
in
cerebrospinal
fluid
(CSF)
serum,
serum
creatinine,
motor
performance
during
nusinersen
treatment
evaluate
as
predictor
outcomes.
Biological
samples
clinical
outcomes
from
34
participants
were
analyzed
at
months,
year,
years,
3
years
post-treatment
initiation.
Most
patients
showed
favorable
outcomes,
with
improved
assessment
scores,
increased
decreased
CSF
serum.
Higher
baseline
was
linked
fewer
SMN2
gene
copies.
The
largest
decrease
occurred
loading
period,
stabilizing
low
through
maintenance.
Smaller
changes
correlated
better
higher
creatinine
Nusinersen
reduced
levels,
reflecting
neuronal
degradation,
enhanced
muscle
activity,
function.
High
SMA
may
indicate
poorer
prognosis
for
improvement.
Язык: Английский
Evolution of Functional and Paraclinical Markers as Predictive Factors in Pediatric Late-Onset SMA Under Nusinersen Treatment: The Role of CSF pNF-H
Balneo and PRM Research Journal,
Год журнала:
2024,
Номер
15(Vol.15, no. 4), С. 755 - 755
Опубликована: Дек. 22, 2024
Spinal
Muscular
Atrophy
(SMA)
is
a
rare
neurodegenerative
disease
caused
by
insufficient
synthesis
of
SMN
protein,
characterized
progressive
muscle
weakness,
atrophy,
and
complications
affecting
the
respiratory
digestive
systems.
Disease
severity
tends
to
be
greater
when
symptoms
manifest
at
an
earlier
age.
Since
2016,
FDA-approved
drug
nusinersen
has
provided
disease-modifying
treatment
option.
Identifying
predictive
factors
for
patient
outcomes
over
time
remains
essential.
This
retrospective
study
analyzed
clinical
biological
parameters
in
42
patients
(ages
13–215
months)
with
SMA
types
2
3
first
three
years
treatment.
We
assessed
pNF-H
levels
CSF
serum—neuronal
proteins
associated
neurodegeneration—as
well
as
serum
creatinine
levels,
marker
activity,
motor
skill
scores
evaluate
pNF-H’s
potential
predictor
development.
Elevated
were
lower
SMN2
gene
copy
number
more
recent
onset.
Following
treatment,
stabilized
low
values,
likely
due
basal
metabolic
activity.
In
3,
higher
baseline
correlated
improved
performance
time.
Additionally,
smaller
changes
during
loading
phase
or
various
periods
maintenance
better
development
two
Язык: Английский